EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients

Zihang Zeng, Zongbi Yi, Binghe Xu

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217574 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025. Verfasst von Zihang Zeng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospit…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 170 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the most prevalent cancers and has emerged as a major global challenge. Circulating tumor DNA (ctDNA), a liquid biopsy method, overcomes the accessibility limitations of tissue-based testing and is widely used for monitoring minimal residual disease and molecular relapse, predicting prognosis, evaluating the response of neoadjuvant therapy, and optimizing treatment decisions in non-metastatic breast cancer. However, the application of ctDNA still faces many challenges. Here, we survey the clinical applications of ctDNA in non-metastatic breast cancer and discuss the significant biological and technical challenges of utilizing ctDNA. Importantly, we investigate potential avenues for addressing the challenges. In addition, emerging technologies, including fragmentomics detection, methylation sequencing, and long-read sequencing, have clinical potential and could be a future direction. Proper utilization of machine learning facilitates the identification of meaningful patterns from complex fragment and methylation profiles of ctDNA. There is still a lack of clinical trials focused on the subsets of ctDNA (e.g., circulating mitochondrial DNA), ctDNA-inferred drug-resistant clonal evolution, tumor heterogeneity, and ctDNA-guided clinical decision-making in non-metastatic breast cancer. Due to regional differences in the number of registered clinical trials, it is essential to enhance communication and foster global collaboration to advance the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNABreast NeoplasmsBiomarkers, TumorHumansFemaleLiquid BiopsyPrognosisDNA Methylation

Stichwörter der Autor:innen

BiomarkersBreast cancerCell-free DNACirculating tumor DNAFragmentomicsLiquid biopsy

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, 430071, Wuhan, China.
  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, 430071, Wuhan, China. Electronic address: yizo…
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China. Electron…

Zitieren

APA

Zeng, Z., Yi, Z., & Xu, B. (2025). The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217574

Vancouver

Zeng Z, Yi Z, Xu B. The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217574

BibTeX
@article{Zeng2025,
  author = {Zeng, Zihang and Yi, Zongbi and Xu, Binghe},
  title = {The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217574}
}
Kostenlos starten →